The CRISPR Confluence: Personalized Medicine’s Leap Forward

Within the next five years, we will witness a significant expansion of CRISPR-Cas9 based therapies moving beyond experimental stages, with several personalized cancer treatments and inherited disease interventions entering widespread clinical use. This will be fueled by advancements in delivery methods, significantly reducing off-target effects and improving efficacy, leading to a paradigm shift in how we approach disease treatment.